share_log

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8：員工福利計劃證券登記
美股sec公告 ·  08/05 16:57
Moomoo AI 已提取核心訊息
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
生物技術公司CRISPR Therapeutics AG於2024年8月5日向證券交易所提交了S-8表格的註冊聲明。該申請旨在爲CRISPR Therapeutics AG 2018年期權和激勵計劃註冊每股CHF 0.03的額外100萬普通股。該舉動旨在方便爲員工和董事發放期權和激勵計劃。本次註冊聲明通過引用先前與2018計劃相關的各項申請的內容。總部位於瑞士楚格，執行辦公室位於馬薩諸塞州南波士頓，被列爲大型加速申報人。本申請還包括各種展品，例如瑞士法律顧問關於普通股有效性的意見以及作爲獨立註冊的上市會計師事務所的Ernst＆Young LLP的同意。
生物技術公司CRISPR Therapeutics AG於2024年8月5日向證券交易所提交了S-8表格的註冊聲明。該申請旨在爲CRISPR Therapeutics AG 2018年期權和激勵計劃註冊每股CHF 0.03的額外100萬普通股。該舉動旨在方便爲員工和董事發放期權和激勵計劃。本次註冊聲明通過引用先前與2018計劃相關的各項申請的內容。總部位於瑞士楚格，執行辦公室位於馬薩諸塞州南波士頓，被列爲大型加速申報人。本申請還包括各種展品，例如瑞士法律顧問關於普通股有效性的意見以及作爲獨立註冊的上市會計師事務所的Ernst＆Young LLP的同意。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息